Real-World Analysis of the Enfortumab Vedotin-Ineligible criTeriA Assessment in Treatment-Naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma

被引：0
|
作者：
Miyake, Makito [1 ]
Nishimura, Nobutaka [1 ]
Oda, Yuki [1 ]
Shimizu, Takuto [1 ]
Iida, Kota [1 ]
Fujimoto, Kiyohide [1 ]
机构：
[1] Nara Med Univ, Dept Urol, Nara, Japan
来源：
INTERNATIONAL JOURNAL OF UROLOGY | 2025年
关键词：
chemotherapy; enfortumab vedotin; EVITA; mortality; pembrolizumab; survival; urinary bladder neoplasms;
D O I：
10.1111/iju.70040
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Real-world use, dose intensity, and adherence to enfortumab vedotin in locally advanced or metastatic urothelial cancer
    Mamtani, Ronac
    Tsingas, Konstantinos
    Parikh, Ravi B.
    Elsouda, Dina
    Mucha, Lisa
    Fuldeore, Rupali
    Hubbard, Rebecca A.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 (06) : e1 - e4
  • [2] Impact of Skin Adverse Events on Prognosis in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin: A Real-World Multicenter Study
    Ozaki, Kai
    Yamamoto, Hayato
    Sekine, Yuya
    Horiguchi, Hirotaka
    Hosogoe, Shogo
    Mikami, Jotaro
    Fujita, Naoki
    Tokui, Noriko
    Okita, Kazutaka
    Okamoto, Teppei
    Mori, Kanami
    Kobayashi, Mizuki
    Numakura, Kazuyuki
    Yoneyama, Takahiro
    Tabata, Ryuji
    Sato, Satoshi
    Habuchi, Tomonori
    Ohyama, Chikara
    Hatakeyama, Shingo
    INTERNATIONAL JOURNAL OF UROLOGY, 2025,
  • [3] Real-world Effectiveness of Single-Agent Enfortumab Vedotin in Patients With Advanced Urothelial Carcinoma
    Sayegh, Nicolas
    Jo, Yeonjung
    Gebrael, Georges
    Tripathi, Nishita
    Chigarira, Beverly
    Srivastava, Ayana
    Nordblad, Blake
    Dal, Emre
    Chehade, Chadi Hage
    Mahlow, Jon
    Maughan, Benjamin L.
    Gupta, Sumati
    Agarwal, Neeraj
    Swami, Umang
    CLINICAL GENITOURINARY CANCER, 2025, 23 (01)
  • [4] Enfortumab Vedotin Nursing perspectives on the management of adverse events in patients with locally advanced or metastatic urothelial carcinoma
    Pace, Amanda
    Brower, Blaine
    Conway, Dawn
    Leis, Dayna
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2021, 25 (02) : E1 - E9
  • [5] Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort
    Miyake, Makito
    Nishimura, Nobutaka
    Oda, Yuki
    Miyamoto, Tatsuki
    Ohmori, Chihiro
    Takamatsu, Norimi
    Itami, Yoshitaka
    Tachibana, Akira
    Matsumoto, Yoshihiro
    Kiba, Keisuke
    Tomioka, Atsushi
    Yamamoto, Hiroaki
    Okajima, Eijiro
    Masaomi, Kuwata
    Sakamoto, Keichi
    Tomizawa, Mitsuru
    Shimizu, Takuto
    Ohnishi, Kenta
    Hori, Shunta
    Morizawa, Yosuke
    Gotoh, Daisuke
    Nakai, Yasushi
    Torimoto, Kazumasa
    Tanaka, Nobumichi
    Fujimoto, Kiyohide
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (03) : 329 - 338
  • [6] Treatment Patterns, Healthcare Resource Utilization, and Costs Among Patients Diagnosed With Locally Advanced/Metastatic Urothelial Carcinoma Prior to Receiving Enfortumab Vedotin: A Real-World Evidence Study
    Morgans, Alicia K.
    Mucha, Lisa
    Quicquaro, Christina
    Shih, Vanessa
    Xie, Bin
    Young, Christopher
    Yang, Hongbo
    Liu, Qing
    Greatsinger, Alexandra
    Lax, Angela
    INTERNATIONAL JOURNAL OF UROLOGY, 2025,
  • [7] Enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial carcinoma: a cost-effectiveness analysis
    Zhu, Youwen
    Liu, Kun
    Zhu, Hong
    Li, Shan
    Yuan, Dan
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2025, 17
  • [8] Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
    O'Donnell, Peter H.
    Milowsky, Matthew I.
    Petrylak, Daniel P.
    Hoimes, Christopher J.
    Flaig, Thomas W.
    Mar, Nataliya
    Moon, Helen H.
    Friedlander, Terence W.
    McKay, Rana R.
    Bilen, Mehmet A.
    Srinivas, Sandy
    Burgess, Earle F.
    Ramamurthy, Chethan
    George, Saby
    Geynisman, Daniel M.
    Bracarda, Sergio
    Borchiellini, Delphine
    Geoffrois, Lionnel
    Rey, Jose Pablo Maroto
    Ferrario, Christiano
    Carret, Anne-Sophie
    Yu, Yao
    Guseva, Maria
    Moreno, Blanca Homet
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (25) : 4107 - +
  • [9] Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort
    Zschaebitz, Stefanie
    Biernath, Nadine
    Hilser, Thomas
    Hoellein, Alexander
    Zengerling, Friedemann
    Cascucelli, Jozefina
    Paffenholz, Pia
    Seidl, Daniel
    Lutz, Christoph
    Schlack, Katrin
    Kingreen, Dorothea
    Kluemper, Niklas
    Ivanyi, Philipp
    von Amsberg, Gunhild
    Heers, Hendrik
    Roghmann, Florian
    Tauber, Robert L.
    Cathomas, Richard
    Hofer, Luisa
    Niegisch, Guenter
    Klee, Melanie
    Ehrenberg, Roland
    Hassler, Andreas
    Hadaschik, Boris A.
    Gruenwald, Viktor
    Darr, Christopher
    EUROPEAN UROLOGY OPEN SCIENCE, 2023, 53 : 31 - 37
  • [10] Real-World Treatment Patterns and Clinical Outcomes in Patients With Locally Advanced or Metastatic Urothelial Carcinoma by Eligibility for Maintenance Avelumab
    Morgans, Alicia K.
    Sonpavde, Guru P.
    Shih, Vanessa
    Wright, Phoebe
    Hepp, Zsolt
    Willmon, Candice L.
    Chang, Nancy N.
    Mucha, Lisa
    Naga, Sai Sriteja Boppudi
    Powles, Thomas
    CLINICAL GENITOURINARY CANCER, 2024, 23 (01)
12345